PRODUCTBRIUMVI^®

BRIUMVI® (ublituximab-xiiy) is a novel, third generation anti-CD20 monoclonal antibody that was approved by the FDA in December 2022 for the treatment of relapsing forms of multiple sclerosis. BRIUMVI targets a unique epitope on the CD20 antigen and is glycoengineered for enhanced potency and antibody-dependent cellular cytotoxicity, allowing for efficient B-cell depletion at low doses.

Background

HealthCare Royalty, alongside funds managed by Blue Owl Capital, provided TG Therapeutics with a credit facility of $250 million (each of HealthCare Royalty and Blue Owl Capital contributing $125 million). An additional $100 million is available at the mutual discretion of the loan participants. This credit facility allows the company to refinance its current debt and support the launch of BRIUMVI, expand commercial infrastructure, increase marketing efforts, and invest in further research and development.